List of Excipients in Branded Drug JAYPIRCA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	CELLULOSE, MICROCRYSTALLINE	2041-09-14
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	CROSCARMELLOSE SODIUM	2041-09-14
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	FD&C BLUE NO. 2 ALUMINUM LAKE	2041-09-14
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	HYPROMELLOSE	2041-09-14
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	HYPROMELLOSE ACETATE SUCCINATE 12070923	2041-09-14
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	LACTOSE MONOHYDRATE	2041-09-14
Eli Lilly and Company	JAYPIRCA	pirtobrutinib	0002-6902	MAGNESIUM STEARATE	2041-09-14

Jaypirca Excipient Strategy and Commercial Opportunities

Last updated: August 30, 2026

Jaypirca (pirtobrutinib) is an oral, small-molecule BTK inhibitor supplied as immediate-release film-coated tablets. Its current excipient platform is conventional and manufacturing-friendly: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, magnesium stearate, sodium lauryl sulfate, hypromellose, talc and titanium dioxide. The principal commercial opportunities are lactose-free reformulation, pediatric or dysphagia-friendly delivery, tablet-manufacturing partnerships, and excipient supply for potential geographic expansion. Because Jaypirca is a small molecule, future competition will come from ANDA-based generics rather than biosimilars.

What excipients are used in Jaypirca tablets?

The U.S. prescribing information identifies the following inactive ingredients for Jaypirca tablets:

Excipient	Likely formulation function
Lactose monohydrate	Diluent and compression aid
Microcrystalline cellulose	Filler, dry binder and tablet-strength contributor
Croscarmellose sodium	Superdisintegrant
Colloidal silicon dioxide	Glidant and moisture-flow aid
Magnesium stearate	Lubricant
Sodium lauryl sulfate	Wetting agent and dissolution aid
Hypromellose	Film-forming coating polymer
Talc	Coating aid and anti-tacking agent
Titanium dioxide	Opacifier and colorant

The tablet core uses a standard direct-compression or dry-granulation excipient architecture. The label does not indicate a modified-release system, enteric coating, lipid vehicle or specialized solubilization technology (U.S. Food and Drug Administration [FDA], 2023).

Jaypirca is marketed in 50-mg and 100-mg film-coated tablet strengths. The formulation is designed for once-daily oral administration, with tablets taken whole and without regard to food. That dosing profile reduces the need for complex release-control excipients and supports conventional high-throughput tablet production.

How does Jaypirca’s excipient strategy affect manufacturing?

Jaypirca’s excipient selection reduces manufacturing complexity and supports multiple contract development and manufacturing organization, or CDMO, options.

Tablet compression and scale-up

Microcrystalline cellulose, lactose and croscarmellose sodium are widely used in oral solid-dose products. Their supply base is broad, which reduces dependence on a single specialty excipient vendor. The formulation can likely be scaled through conventional blending, lubrication and compression operations, subject to process parameters protected by Lilly’s manufacturing controls and any applicable patent claims.

The main manufacturing risks are:

• Blend uniformity at low drug-load conditions.
• Powder segregation between pirtobrutinib and diluents.
• Magnesium stearate over-lubrication, which can reduce tablet hardness or slow dissolution.
• Sodium lauryl sulfate variability, which can affect wetting and dissolution.
• Film-coating weight gain and color consistency across 50-mg and 100-mg strengths.
• Moisture sensitivity during storage and packaging.

Pirtobrutinib is a potent active pharmaceutical ingredient, so the amount of drug per tablet is relatively small compared with the total tablet mass. That increases the importance of content-uniformity controls and blend sampling strategy.

Excipient sourcing

The core excipients are commodity or broadly available pharmaceutical ingredients. The strongest supplier opportunities are therefore unlikely to arise from exclusive access to a unique excipient. They are more likely to arise from:

1. Qualified dual sourcing.
2. Low-nitrite or low-peroxide excipient grades.
3. Consistent particle-size distributions.
4. Direct-compression grades with improved flow.
5. Regional supply and regulatory support.
6. Integrated excipient-plus-process packages for generic manufacturers.

Excipient companies with strong regulatory documentation, global GMP coverage and reliable supply continuity can compete for Jaypirca-related business even when the excipients themselves are not novel.

What excipient-related commercial opportunities exist for Jaypirca?

Lactose-free Jaypirca alternatives

Lactose monohydrate is the clearest formulation opportunity. It is widely accepted, but some patients avoid lactose because of intolerance, dietary preference or excipient sensitivity. A lactose-free tablet could replace lactose with mannitol, anhydrous dibasic calcium phosphate, silicified microcrystalline cellulose, pregelatinized starch or a co-processed filler.

A replacement would need to preserve:

• Tablet hardness.
• Disintegration time.
• Dissolution across relevant pH conditions.
• Content uniformity.
• Moisture stability.
• Compression speed.
• Tablet size and swallowability.

A lactose-free version would have the strongest commercial value if it could be introduced without changing the active dose, dosing instructions or bioavailability. It could also create a differentiated product for markets where lactose-free labeling has commercial importance.

Dysphagia-friendly and geriatric dosage forms

Jaypirca is used primarily in hematologic malignancies, including mantle cell lymphoma and chronic lymphocytic leukemia or small lymphocytic lymphoma. These populations include older adults and patients with treatment-related swallowing difficulties. A formulation that disperses rapidly in water, or a smaller tablet with improved swallowability, could address an important administration barrier.

Potential formats include:

• Orally disintegrating tablets.
• Mini-tablets.
• Dispersible tablets.
• Powder-for-suspension sachets.
• Extemporaneous oral suspension kits.

The principal regulatory issue is whether the alternative dosage form would be treated as a new dosage form requiring a separate application or as a reformulation supported by bridging data. Taste masking would also be important because pirtobrutinib is not currently marketed as a liquid product.

Pediatric and adolescent formulations

Pediatric oncology is a longer-term opportunity. A liquid or dispersible formulation could support weight-based dosing and administration to patients unable to swallow tablets. The commercial case depends on pediatric labeling, clinical demand and the development of age-appropriate dosing.

Suitable excipient platforms could include:

• Hydroxypropyl cellulose or hypromellose as suspending or viscosity-modifying agents.
• Poloxamers or polysorbates as wetting agents.
• Citrate or phosphate buffers.
• Sugars or polyols for palatability.
• Low-risk preservatives where justified.

A pediatric product would need careful control of alcohol, propylene glycol, benzyl alcohol, sugars and other excipients with age-related safety concerns. It would also require extractables and leachables testing for bottles, syringes and dosing devices.

Low-sodium and dietary-positioning opportunities

Sodium lauryl sulfate is present at low formulation levels as a wetting agent. A reformulation could evaluate nonionic surfactants or alternative wetting systems. The commercial value of a low-sodium claim is likely limited because the amount of sodium contributed by sodium lauryl sulfate is expected to be small, but the change could improve positioning for patients requiring tightly controlled excipient exposure.

A larger opportunity may be a simplified excipient declaration for patients with multiple medications, polypharmacy or documented excipient intolerance.

How does Jaypirca compare with competing BTK inhibitors?

Jaypirca competes in a BTK inhibitor market that includes Imbruvica (ibrutinib), Calquence (acalabrutinib) and Brukinsa (zanubrutinib). All are oral small-molecule products, so the relevant competitive factors include selectivity, tolerability, dosing, food requirements, drug interactions, tablet or capsule burden and disease-line positioning.

Product	Active ingredient	Dosage-form profile	Excipient opportunity
Jaypirca	Pirtobrutinib	Immediate-release film-coated tablets	Lactose-free, dispersible or pediatric formats
Imbruvica	Ibrutinib	Capsules and tablets, depending on presentation	Generic manufacturing and alternate solid-dose platforms
Calquence	Acalabrutinib	Tablets and capsules	Low-interaction and patient-preference formulations
Brukinsa	Zanubrutinib	Capsules and tablets	Capsule-to-tablet conversion and adherence-focused formats

Jaypirca’s commercial differentiation is primarily pharmacologic and clinical. Excipient differentiation can support adherence, access and patient segmentation, but it is unlikely to replace the importance of efficacy, safety and treatment-line positioning.

When does Jaypirca lose exclusivity?

Jaypirca received accelerated FDA approval in November 2023 for adult patients with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a BTK inhibitor. The FDA expanded the label in December 2023 for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma after prior treatment with a covalent BTK inhibitor and a BCL-2 inhibitor, or after covalent BTK inhibitor treatment where BCL-2 inhibitor therapy was not suitable (FDA, 2023a; FDA, 2023b).

The commercial exclusivity analysis has several separate components:

Exclusivity category	Jaypirca relevance
New chemical entity exclusivity	Typically five years from initial approval for a small molecule
Orphan-drug exclusivity	Depends on the specific indication and orphan designation
Patent exclusivity	Depends on issued claims, terminal disclaimers, PTA and any litigation outcome
Pediatric exclusivity	Six-month extension if qualifying pediatric studies are completed
Regulatory exclusivity for new indications	Depends on approval pathway and statutory requirements
Generic approval timing	May be delayed by listed patents and Paragraph IV litigation

The initial approval date alone does not establish the final generic-entry date. FDA exclusivity, Orange Book-listed patents, patent-term adjustment, pediatric extensions and litigation settlements must be reviewed together. Jaypirca is a small molecule, so the relevant abbreviated pathway is an ANDA rather than a biosimilar application.

What is the Orange Book and Paragraph IV risk for Jaypirca?

Jaypirca’s generic risk will depend on the patents listed in the FDA Orange Book and the scope of claims covering pirtobrutinib, its pharmaceutical compositions, methods of treatment and manufacturing processes. An ANDA applicant can submit a Paragraph IV certification asserting that a listed patent is invalid, unenforceable or not infringed.

The likely generic strategies include:

• Paragraph IV challenges to composition-of-matter patents.
• Carve-outs for patented methods of use.
• Non-infringement positions based on different excipient systems.
• Alternative polymorph, salt or crystalline-form arguments where legally available.
• Process-based non-infringement strategies.
• Formulation changes that avoid claimed excipient combinations.

Excipient substitution can help a generic applicant avoid a narrow formulation claim, but it does not avoid a composition-of-matter patent covering pirtobrutinib itself. For this reason, lactose replacement has greater strategic value for product differentiation and patient access than for eliminating core patent risk.

What formulation patents could protect Jaypirca alternatives?

A reformulated Jaypirca product could potentially support patent claims directed to:

• A specific excipient combination.
• A defined dissolution profile.
• Improved chemical or physical stability.
• Reduced tablet size.
• Improved content uniformity.
• A lactose-free composition.
• An orally disintegrating or dispersible tablet.
• A liquid suspension with controlled particle size.
• A manufacturing process that reduces degradation products.
• A packaging system that controls moisture or oxygen exposure.

The strongest formulation patent position would normally require a measurable technical effect, such as improved stability, dissolution, bioavailability, manufacturability or patient administration. A simple substitution of lactose with another conventional filler may be commercially useful but can be difficult to defend as an inventive formulation without supporting comparative data.

What licensing and partnership opportunities exist?

Potential counterparties include Lilly, specialty excipient manufacturers, generic drug companies, oncology-focused CDMOs and drug-delivery developers.

The most credible deal structures are:

Opportunity	Likely partner	Commercial rationale
Lactose-free tablet platform	Lilly or a generic applicant	Patient segmentation and market access
Direct-compression excipient package	Excipient supplier and CDMO	Lower scale-up risk
Dispersible tablet	Drug-delivery company	Swallowability and older-patient use
Oral suspension	Pediatric formulation specialist	Weight-based dosing and administration flexibility
Regional manufacturing	Local pharmaceutical manufacturer	Supply security and geographic access
Generic development	ANDA sponsor and CDMO	Post-exclusivity market entry
Stability and packaging program	Packaging supplier	Shelf-life and distribution control

A licensing opportunity is more defensible when the excipient platform produces a documented technical advantage rather than merely replacing one standard filler with another.

What geographic opportunities exist for Jaypirca excipients?

The U.S. is the most visible reference market because the FDA label defines the current commercial tablet platform. International opportunities depend on national approvals, local packaging requirements, excipient acceptability and supply-chain economics.

Regional formulation considerations include:

• European and United Kingdom excipient labeling requirements.
• Local requirements for lactose declaration.
• Pharmacopoeial compliance with USP-NF, Ph. Eur. or other standards.
• Climate-zone stability testing.
• Regional blister and bottle configurations.
• Local manufacturing or technology-transfer requirements.
• Availability of pharmaceutical-grade direct-compression excipients.

A supplier with dual-region manufacturing and complete quality documentation can create value through supply assurance rather than ingredient novelty.

How strong is the Jaypirca excipient opportunity?

The opportunity is moderate for differentiated delivery and strong for generic manufacturing support. It is weaker for a premium product based solely on commodity excipient substitution.

Segment	Opportunity	Main barrier
Commodity excipient supply	Moderate	Multiple qualified suppliers
Lactose-free formulation	Moderate to strong	Need to preserve dissolution and stability
Smaller or dispersible tablet	Strong	Clinical, regulatory and IP validation
Pediatric suspension	Moderate	Pediatric development and taste masking
Generic tablet manufacturing	Strong after patent barriers	Core patent and regulatory timing
Novel excipient system	Limited near term	Safety, regulatory and scale-up burden
Biosimilar development	Not applicable	Jaypirca is a small molecule

Key Takeaways

• Jaypirca uses a conventional immediate-release film-coated tablet platform.
• Lactose monohydrate is the clearest excipient target for differentiated reformulation.
• Microcrystalline cellulose, croscarmellose sodium, magnesium stearate and sodium lauryl sulfate support standard tablet manufacturing.
• Dysphagia-friendly, dispersible, pediatric and liquid formats offer higher-value opportunities than simple excipient replacement.
• Jaypirca faces generic, not biosimilar, competition.
• Excipient substitution may avoid narrow formulation claims but will not overcome a valid composition-of-matter patent.
• The best commercial opportunities combine formulation differentiation with manufacturing reliability, regulatory support and geographic supply capacity.

FAQs

Can Jaypirca be reformulated without lactose?

Yes. Lactose could potentially be replaced with mannitol, anhydrous dibasic calcium phosphate, pregelatinized starch or a co-processed filler. The replacement must maintain dissolution, content uniformity, tablet strength and stability.

Is Jaypirca available as a liquid oral suspension?

The U.S. product is marketed as film-coated tablets. A liquid suspension would require a separate formulation and regulatory assessment, with taste masking, dose uniformity and pediatric excipient safety as central development issues.

Does Jaypirca have biosimilar competition?

No. Pirtobrutinib is a small molecule. Future follow-on products would generally use the generic-drug pathway rather than the biosimilar pathway.

Can a generic Jaypirca use different excipients?

Yes, subject to applicable ANDA requirements and product-performance standards. A generic may use a different excipient system if it demonstrates pharmaceutical equivalence and bioequivalence and complies with safety and labeling requirements.

Which excipient offers the strongest commercial differentiation?

Lactose replacement has the clearest near-term opportunity. A dispersible or pediatric dosage form could generate greater differentiation but would require substantially more development, regulatory work and supporting data.

References

1. U.S. Food and Drug Administration. (2023). Jaypirca (pirtobrutinib) prescribing information. Eli Lilly and Company.

2. U.S. Food and Drug Administration. (2023a). FDA grants accelerated approval to pirtobrutinib for mantle cell lymphoma. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2023b). FDA grants accelerated approval to pirtobrutinib for chronic lymphocytic leukemia and small lymphocytic lymphoma. https://www.fda.gov/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP-NF.